Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in clinical chemoprevention

G J Kelloff1, E T Hawk, J E Karp

  • 1Division of Cancer Prevention and Control, Chemoprevention Branch, National Cancer Institute, Bethesda, MD 20852, USA.

Seminars in Oncology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Clinical pharmacology and therapeutics·2017
Same author

Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform.

Clinical pharmacology and therapeutics·2017
Same author

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Clinical pharmacology and therapeutics·2009
Same author

Can breast cancer be prevented?

Annals of Saudi medicine·2007
Same author

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis.

Gastroenterology·2004

Chemoprevention aims to inhibit carcinogens and treat precancerous lesions. The National Cancer Institute

Area of Science:

  • Oncology
  • Preventive Medicine
  • Molecular Biology

Background:

  • Chemoprevention targets four key areas: carcinogen inhibition, genetic risk intervention, precancerous lesion treatment, and translating dietary findings into strategies.
  • The National Cancer Institute (NCI) has developed a multidisciplinary, science-based program for chemopreventive drug development.
  • Collaboration with the US Food and Drug Administration (FDA) provides guidance for implementing chemoprevention strategies.

Purpose of the Study:

  • To outline the goals and multidisciplinary approach of the NCI's chemopreventive drug development program.
  • To emphasize the importance of identifying and validating intermediate biomarkers as surrogate endpoints in clinical trials.
  • To highlight the role of advancing molecular carcinogenesis knowledge and the Human Genome Project in future chemoprevention.

Related Experiment Videos

Main Methods:

  • Development of a multidisciplinary, cancer science-based program for drug discovery.
  • Collaboration with regulatory bodies (FDA) for consensus guidance.
  • Focus on identifying and characterizing intermediate biomarkers in Phase II clinical studies.
  • Utilizing knowledge from molecular carcinogenesis and the Human Genome Project.

Main Results:

  • Over 40 agents are in clinical development, with a significant focus on Phase II studies for biomarker characterization.
  • Advancing understanding of carcinogenesis mechanisms is leading to more specific and less toxic chemopreventive agents.
  • The Human Genome Project is expected to aid in identifying at-risk populations and specific targets for intervention.

Conclusions:

  • Chemoprevention is a multifaceted strategy with a robust drug development program guided by scientific advancement.
  • Biomarker validation is crucial for the success of clinical chemoprevention trials.
  • Future chemoprevention will benefit from molecular insights and genetic risk assessments.